A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias (NCT07491172)
A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias
🩺 Plain-English Summary (8th-Grade Level)
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.
Who can join: Review the eligibility criteria below.
Location: Integrity Clinical Research — Hialeah, Florida
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Integrity Clinical Research — Hialeah, Florida
- Jacksonville Center for Clinical Research — Jacksonville, Florida
- Flourish Orlando — Orlando, Florida
- United Medical Research — Port Orange, Florida
- University of Rochester — Rochester, New York
- Duke Early Phase Clinical Research — Durham, North Carolina
- Peters Medical Research — High Point, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- Oregon Health & Science University (OHSU) — Portland, Oregon
- Royal Adelaide — Adelaide,
- CORE Research — Brisbane,
- Royal Prince Alfred Hospital — Camperdown,
- Austin Health — Heidelberg,
- Monash Medical Center — Melbourne,
- Aotearoa — Auckland,
- NZCR — Christchurch,
- Royal Papworth Hospital — Cambridge,
- Barts — London,
- Richmond Pharmacology — London,
📞 Contact the Study Coordinator
Phone: (877) 214-4634
Email: medicalaffairs@crisprtx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cardiovascular
- A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia — Glendale, California
- The Role of EDHFs on Blood Pressure Following a Bout of Prolonged Sitting — Halifax, Nova Scotia
- Improving the Heart Health of Home Health Aides — New York, New York
- Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities — Birmingham, Alabama
Explore by condition: All Cardiovascular clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.